Donald Picker Buys Shares of MBRX
MBRX's Chief Science Officer, Donald Picker, purchased 71 shares on June 22, 2026.
Key Points
- Donald Picker, MBRX's Chief Science Officer, bought 71 shares on June 22, 2026, signaling insider interest.
- MBRX shares traded at $2.93 on Thursday, with significant insider transactions occurring recently.
- SABBY MANAGEMENT, LLC and others opened new positions in MBRX, while analysts maintain a positive outlook.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Donald Picker, the Chief Science Officer of MBRX, made a notable move by purchasing 71 shares of the company on June 22, 2026. This transaction was not part of a pre-planned trading scheme, indicating a potential vote of confidence from within the company.
Insider Buying and Selling at Moleculin Biotech, Inc.
Alongside Picker's purchase, there were several other insider transactions on the same day. Picker also sold 21 shares at $3.12 each and another 71 shares at no disclosed price. Walter Klemp, the CEO and President, sold 360 shares, and Jonathan Foster, the Chief Financial Officer, sold 41 shares at $3.12. Foster also bought 174 shares, adding to the mix of insider activity.
Other Institutional Activity in MBRX
In recent institutional activities, SABBY MANAGEMENT, LLC opened a new position in MBRX with 75,021 shares valued at approximately $171,798. GEODE CAPITAL MANAGEMENT, LLC increased its holdings by 17,191 shares, bringing its total to 32,329 shares worth about $74,033, marking a 113.6% increase. VANGUARD CAPITAL MANAGEMENT LLC and HRT FINANCIAL LP also initiated new positions, acquiring 13,869 and 13,739 shares respectively. ROCKEFELLER CAPITAL MANAGEMENT L.P. added 4,203 shares, a significant increase of 1,928%, resulting in a total of 4,421 shares valued at $10,124.
Analysts Set New Price Targets
Analysts have shown continued optimism for MBRX. On March 24, 2026, HC Wainwright & Co. reiterated its buy rating with a price target of $22. This follows several previous buy ratings and targets by both HC Wainwright & Co. and Maxim Group, with targets ranging from $4 to $40, reflecting varied expectations.
Bottom Line
Donald Picker's recent share purchase adds to a series of insider transactions at MBRX, capturing investor interest. While insider activity can provide insights, it's important to remember that these transactions may not always predict future stock performance. Institutional and analyst actions suggest varied expectations for MBRX, highlighting the stock's dynamic market position.
Get Moleculin Biotech, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MBRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.